http://orcid.org/0000-0001-9568-0894
References
- Tiribelli M, Binotto G, Bonifacio M. The significance of early warning in chronic myeloid leukemia. Expert Rev Hematol. 2017 Jun 9. doi:10.1080/17474086.2017.1340715. [Epub ahead of print]
- Eskazan AE, Ar MC, Soysal T. Critical appraisal of European LeukemiaNet (ELN) 2013 recommendations for the management of chronic myeloid leukemia: is it early for a warning? Expert Rev Hematol. 2016;9(10):919–921.
- Bonifacio M, Binotto G, Maino E, et al. Imatinib-treated CML patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response. Haematologica. 2015;100(8):e299–e301.
- Qin YZ, Jiang Q, Lai YY, et al. Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib. Leuk Lymphoma. 2017;58(6):1384–1393.
- Binotto G, Tiribelli M, Bonifacio M, et al. BCR-ABL fusion transcript b2a2 is associated with a higher risk of non-optimal response in CP-CML patients treated with standard dose imatinib: a study from Gruppo Triveneto LMC. Haematologica. 2016;101(s1):454. [abstract].
- Jain P, Kantarjian HM, Patel KP, et al. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016;127(10):1269–1275.